Hello Anthony, I am not an expert but this, and all other, NDA's that I am aware of, goes before a FDA Advisory Committee, which makes a recommendation to the FDA panel that actually issues its verdict.
I think it used to be pretty much a slam dunk that the FDA panel followed the FDA advisory committee, but not any more. We can thank Viox and others for final verdicts being much harder in the industry of late.
Still, my guess would be that should the Advisory Committee recommend Imagify, the share price goes somewhat skyward as the odds of imagify getting approved would be looked at in a much more favorable light, as investors looked at the potential of the 2 BILLION dollar market Imagify would compete in.
I am not sure of what time frame, from the Dec. 10th meeting, can be considered "normal" for the advisory committee to either recommend, or not recommend, but I would be very interested to hear what others had to say on that subject.
Take Care.
Market Data 
Markets 
AI
